05B4 Whellan - Thomas Jefferson University - Thomas Jefferson University
djw150

David J. Whellan, MD, MHS, FACC, FAHA

Contact Dr. Whellan

1015 Chestnut Street
Suite 317
Philadelphia, PA 19107

(215) 955-2007
(215) 503-7420 fax

Most Recent Peer-reviewed Publications

  1. Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial
  2. Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis
  3. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)
  4. Conceptual model for heart failure disease management
  5. Rationale and Design of theGUIDE-ITStudy. Guiding Evidence Based Therapy UsingBiomarker Intensified Treatment inHeart Failure
  6. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure
  7. End-of-life care in patients with heart failure
  8. Are there negative responders to exercise training among heart failure patients?
  9. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: Results of two 6-month, phase 3 studies
  10. Clinical implications of chronic heart failure phenotypes defined by cluster analysis
  11. Rationale and design of theguide-it study: Guiding evidence based therapy usingbiomarker intensified treatment inheart failure
  12. Aspirin for cardioprotection and strategies to improve patient adherence.
  13. 08B3
  14. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure
  15. Associations between Seattle heart failure model scores and medical resource use and costs: Findings from HF-ACTION
  16. Relationship between galectin-3 LEVELS and MINERALOCORTICOID RECEPTOR ANTAGONIST USE in HEART FAILURE: Analysis from HF-ACTION
  17. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: A randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study
0